Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

KALV - KalVista Pharmaceuticals, Inc.

IEX Last Trade
8.76
-1.920   -21.918%

Share volume: 0
Last Updated: Tue 24 Dec 2024 06:10:50 PM CET
Research and Development in Biotechnology (except Nanobiotechnology): 35.29%

PREVIOUS CLOSE
CHG
CHG%
$10.68
-1.92
-17.98%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
25%
Profitability 25%
Dept financing 4%
Liquidity 75%
Performance 18%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
4.78%
1 Month
-13.01%
3 Months
-7.40%
6 Months
-24.16%
1 Year
-24.97%
2 Year
48.98%
Key data
Stock price
$8.76
P/E Ratio 
-15.23
DAY RANGE
$8.64 - $10.68
EPS 
-$2.12
52 WEEK RANGE
$8.55 - $16.88
52 WEEK CHANGE
-$27.24
MARKET CAP 
576.867 M
YIELD 
N/A
SHARES OUTSTANDING 
43.082 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
09/05/2024
BETA 
1.08
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$598,783
AVERAGE 30 VOLUME 
$428,581
Company detail
CEO: T. Andrew Crockett
Region: US
Website: kalvista.com
Employees: 100
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

KalVista Pharmaceuticals, Inc. discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME) products.

Recent news